CN1415615A - New compound of natrium cefdinir - Google Patents
New compound of natrium cefdinir Download PDFInfo
- Publication number
- CN1415615A CN1415615A CN 02146335 CN02146335A CN1415615A CN 1415615 A CN1415615 A CN 1415615A CN 02146335 CN02146335 CN 02146335 CN 02146335 A CN02146335 A CN 02146335A CN 1415615 A CN1415615 A CN 1415615A
- Authority
- CN
- China
- Prior art keywords
- cefdinir
- new compound
- natrium
- sodium
- mol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Cephalosporin Compounds (AREA)
Abstract
A novel compound, cephalosporin Toubaodinina, for treating the infection caused by sensitive bacteria, or child infection is prepared through the reaction of Toubaodini on sodium dicarbonate, deposition in alcohol, filter, and low-temp vacuum drying. Its advantages are high water solubility and easy absorption for oral application.
Description
Technical field
The present invention relates to nitrogenous and heterogeneous ring compound sulphur; particularly relate to Cefdinir sodium (title is [6R-[6 α, 7 β (Z)]]-7-[[(2-amino-4-thiazolyl)-(oximido) ethanoyl] amino]-3-vinyl-8-oxygen-5-thia-1-azabicyclic [4.2.0] oct-2-ene-2-carboxylic acid sodium).
Background technology
Because Cefdinir is water insoluble, as antibiotic medicine, oral post-absorption is bad, therefore, changes the water-soluble of Cefdinir, become now urgent problem it
Summary of the invention
The objective of the invention is to overcome above-mentioned the deficiencies in the prior art part, and provide a kind of synthetic convenience, the new Cefdinir sodium of good water solubility.
The object of the invention can reach by following measure: it is at normal temperatures and pressures, carry out complete reaction by 1 mol Cefdinir and 1 mol sodium bicarbonate after, add ethanol sedimentation, suction filtration, low-temperature vacuum drying promptly obtains this patent product Cefdinir sodium.
Reaction formula is:
Character:
Fusing point: not clear, 160 ℃ of left and right sides flavescence slowly increase the weight of to be brown afterwards, and 190 ℃ of left and right sides blackening and decomposing are yellow crystalline powder, and odorless or slightly special smell are soluble in water.
Product of the present invention has following advantage compared to existing technology: because this product is synthetic uncomplicated, be antibiotic medicine, soluble in water, oral absorption is good, has improved drug effect.
Embodiment
Embodiment 1
At normal temperatures and pressures, 1 mol Cefdinir and 1 mol sodium bicarbonate are put into reaction flask constantly stir, after reacting completely, in bottle, add ethanol sedimentation, suction filtration, low-temperature vacuum drying promptly obtains this patent product Cefdinir sodium.
Purposes:
Cefdinir is a third generation cephalosporin, indication be due to the various sensitive strains in, severe infection, also can be used for paediatrics and infect.
Compare with s-generation cephalo, the third generation cephalosporin antimicrobial spectrum is wider, anti-microbial activity is stronger, more stable to bacteriogenic β-Nei Xiananmei, especially more stable to the I fermentoid, therefore have stronger sterilizing ability to producing I zymoid negative bacillus such as enterobacteria, Serratia and Pseudomonas aeruginosa, its super broad-spectrum antibacterial action has covered most Gram-negatives and positive bacteria, particularly to the gram-positive microorganism effect than two generation cynnematin obviously strengthen.
Claims (1)
1, a kind of new compound Cefdinir sodium, its feature at normal temperatures and pressures, carry out complete reaction by 1 mol Cefdinir and 1 mol sodium bicarbonate after, add ethanol sedimentation, suction filtration, low-temperature vacuum drying promptly obtains this patent product.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02146335 CN1415615A (en) | 2002-10-24 | 2002-10-24 | New compound of natrium cefdinir |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02146335 CN1415615A (en) | 2002-10-24 | 2002-10-24 | New compound of natrium cefdinir |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1415615A true CN1415615A (en) | 2003-05-07 |
Family
ID=4751052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02146335 Pending CN1415615A (en) | 2002-10-24 | 2002-10-24 | New compound of natrium cefdinir |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1415615A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100381445C (en) * | 2003-11-05 | 2008-04-16 | 余安国 | Cefetamet sodium and its application of preparing powder injection or dry powder injection for broad-spectrum strong antibiotic injection |
WO2010075765A1 (en) | 2008-12-31 | 2010-07-08 | 浙江奥默生物医药有限公司 | Cefdinir acid double salt and its preparation |
-
2002
- 2002-10-24 CN CN 02146335 patent/CN1415615A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100381445C (en) * | 2003-11-05 | 2008-04-16 | 余安国 | Cefetamet sodium and its application of preparing powder injection or dry powder injection for broad-spectrum strong antibiotic injection |
WO2010075765A1 (en) | 2008-12-31 | 2010-07-08 | 浙江奥默生物医药有限公司 | Cefdinir acid double salt and its preparation |
CN101481383B (en) * | 2008-12-31 | 2012-01-11 | 杭州奥默医药技术有限公司 | Cefdinir acid type double salt compound and preparation |
RU2531276C2 (en) * | 2008-12-31 | 2014-10-20 | Чжецзян Адамерк Биофармлабс Инк. | Cefdinir acid salt and method of obtaining thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Carlsson et al. | Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine | |
EP2642992B1 (en) | Compounds and their use | |
CN102871996A (en) | Antibiotic composition and application thereof | |
CN105061472A (en) | One-pot synthesis method of ceftriaxone sodium | |
US20160009733A1 (en) | Regulation of nitric oxide release and biofilm development | |
CN103102357B (en) | A kind of synthetic method of Cefuroxime sodium | |
CA2510949A1 (en) | Polymorph of ritonavir | |
CN1415615A (en) | New compound of natrium cefdinir | |
CN111744016B (en) | Application of compound amino acid in preparation of medicine for improving sensitivity of bacteria to antibiotics | |
CN105418641A (en) | Original-quality ceftriaxone sodium and pharmaceutical preparation thereof | |
CN101172974A (en) | Method for producing aztreonam amino acid salt | |
CA2180689A1 (en) | Use of lactoferrin for therapy of acute or recurrent infectious diseases by streptococcus pyogenes or other intracellular gram positive pathogen bacteria | |
CN101787037B (en) | High-purified cefotiam hydrochloride compound | |
CN102627660B (en) | Cefmetazole aseptic powder and its preparation method | |
KR101435433B1 (en) | Antibacterial hand sanitizer comprising nano clay | |
CN100381445C (en) | Cefetamet sodium and its application of preparing powder injection or dry powder injection for broad-spectrum strong antibiotic injection | |
JP5660633B2 (en) | Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infections | |
Legakis et al. | In vitro activity of ticarcillin, carbenicillin and ampicillin against some Gram-negative bacilli | |
CN102807573B (en) | Method for preparing ceftizoxime | |
CA1181741A (en) | Water soluble derivatives of cephalexin and process for their preparation | |
CN103550169A (en) | Cefpodoxime proxetil composition freeze-dried powder injection for injection | |
CN103627773A (en) | Fermentation technology of cephalosporin | |
PE20040679A1 (en) | POLYPEPTIDE T1249 STICKED | |
EP1180019A1 (en) | Antibiotic-natural polysaccharide polymer adducts | |
JPS6344128B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |